Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB): a meta-analysis

被引：0
|
作者：
Flacco, M. E. [1 ]
Manzoli, L. [2 ]
Rosso, A. [3 ]
Marzuillo, C. [3 ]
Bergamini, M. [4 ]
Stefanati, A. [4 ]
Villari, P. [3 ]
Ricciardi, W. [5 ]
Ioannidis, J. P. [6 ]
Contopoulos-Ioannidis, D. G. [7 ]
机构：
[1] Local Hlth Unit, Pescara, Italy
[2] Local Hlth Unit, Ferrara, Italy
[3] Sapienza Univ, Dept Publ Hlth & Infect Dis, Rome, Italy
[4] Univ Ferrara, Ferrara, Italy
[5] Italian Natl Inst Hlth, Rome, Italy
[6] Stanford Prevent Res Ctr, Stanford, CA USA
[7] Dept Pediat, Stanford, CA USA
来源：
EUROPEAN JOURNAL OF PUBLIC HEALTH | 2017年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)
    Bettinger, Julie A.
    Scheifele, David W.
    Halperin, Scott A.
    Vaudry, Wendy
    Findlow, Jamie
    Borrow, Ray
    Medini, Duccio
    Tsang, Raymond
    VACCINE, 2013, 32 (01) : 124 - 130
  • [42] A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II) Effects of variations of the OMV and protein content on immunogenicity and reactogenicity
    Esposito, Susanna
    Prymula, Roman
    Zuccotti, Gian Vincenzo
    Xie, Fang
    Barone, Michelangelo
    Dull, Peter M.
    Toneatto, Daniela
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 2005 - 2014
  • [43] Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada
    De Serres, Gaston
    Billard, Marie-Noelle
    Gariepy, Marie-Claude
    Rouleau, Isabelle
    Toth, Eveline
    Landry, Monique
    Boulianne, Nicole
    Gagne, Helene
    Gilca, Vladimir
    Deceuninck, Genevieve
    Ouakki, Manale
    Skowronski, Danuta M.
    VACCINE, 2018, 36 (52) : 8039 - 8046
  • [44] A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I) Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB
    Prymula, Roman
    Esposito, Susanna
    Zuccotti, Gian Vincenzo
    Xie, Fang
    Toneatto, Daniela
    Kohl, Igor
    Dull, Peter M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1993 - 2004
  • [45] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    Miguel O’Ryan
    Jeffrey Stoddard
    Daniela Toneatto
    James Wassil
    Peter M. Dull
    Drugs, 2014, 74 : 15 - 30
  • [46] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    O'Ryan, Miguel
    Stoddard, Jeffrey
    Toneatto, Daniela
    Wassil, James
    Dull, Peter M.
    DRUGS, 2014, 74 (01) : 15 - 30
  • [47] Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations
    Fernandez-Prada, Maria
    Martinez-Ortega, Carmen
    Hidalgo-Pena, Lara
    Alvarez-Vazquez, Clara
    Aguirre-Del Pino, Rodrigo
    Huerta-Gonzalez, Ismael
    FARMACIA HOSPITALARIA, 2018, 42 (05) : 191 - 196
  • [48] Post-licensure observational safety study after meningococcal B Vaccine (4CMenB) vaccination in routine UK care
    Hall, Gillian C.
    Douglas, Ian
    Heath, Paul T.
    Prabhakar, Prab
    Rosillon, Dominique
    Khan, Javeed
    Abbing-Karahagopian, Victoria
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 620 - 620
  • [49] Impact of Meningococcal B (4CMenB) Vaccine on Pharyngeal Neisseria meningitidis Carriage Density and Persistence in Adolescents
    McMillan, Mark
    Walters, Luke
    Sullivan, Thomas
    Leong, Lex E. X.
    Turra, Mark
    Lawrence, Andrew
    Koehler, Ann P.
    Finn, Adam
    Andrews, Ross M.
    Marshall, Helen S.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : E99 - E106
  • [50] Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents
    Argante, Lorenzo
    Prunas, Ottavia
    Medini, Duccio
    Ypma, Ellen
    NPJ VACCINES, 2024, 9 (01)
12345